In the context of increasing reports of yeast resistance to conventional antifungal therapy, the use of lactoferrin (both human lactoferrin (hLf) and bovine lactoferrin (bLf)) may represent a promising strategy to support treatment and reduce the recurrence of infections within the urogenital and gastrointestinal tracts in both pregnant women and infants. This evidence concerns the gene LTF and infection.